צמיחת מכירות משנה לשנה (TTM): OnKure Therapeutics (OKUR)

OnKure Therapeutics Inc (OKUR) is developing targeted cancer therapies in its US laboratories. The trailing four-quarter revenue growth rate demonstrates the business's scaling dynamics, where the 0.00 mark indicates the current consensus level. The asset is entirely non-cyclical and resilient to macro shocks; however, a narrow specialization in small molecules creates high binary risks typical of venture biotech firms.
OnKure Therapeutics Inc - פילוחים אנליטיים ומדדי מפתח (OKUR)

OnKure Therapeutics Inc (OKUR) invests in the development of precision oncology drugs and targeted DNA inhibitors. The momentum of these developments converts into revenue, which the metric compares over a trailing twelve-month (LTM) period. This indicator measures the percentage deviation of current revenues from the same period last year, allowing for a real-time assessment of technology commercialization rates. By analyzing the LTM change in commercial revenue, an investor can determine the business's scaling stage.